Trial Profile

A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2737 in Orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GLPG 2737 (Primary)
Indications Cystic fibrosis
Focus Therapeutic Use
Acronyms PELICAN
Sponsors Galapagos NV; Lakefront Biotherapeutics

Most Recent Events

07 May 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
28 Jun 2018 Primary endpoint has been met. (Change from baseline in sweat chloride concentration compared to placebo), according to a Galapagos NV media release.,
28 Jun 2018 According to a Galapagos NV media release, details of this study will be presented at a future conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com